Developing vaccines against foot-and-mouth disease and some other exotic viral diseases of livestock

Vaccines remain the main tool for the control of livestock viral diseases that pose a serious threat to animal and occasionally human health, reduce food security, distort trade in animals and their products, and undermine agricultural development in poor countries. Globalization and climate change increase the likelihood for new patterns of emergence and spread of livestock viruses. Conventionally attenuated and killed virus products have had spectacular success, and recent examples include the global eradication of rinderpest and the control of bluetongue in the UK and northern Europe. However, in many cases, livestock vaccines could benefit from improvement in some properties (e.g. stability, speed of onset and duration of immunity, and breadth of cross-protection to different serotypes or strains) and in some cases are not available at all. Compared with human vaccines, uptake of livestock products is highly cost-sensitive and their use may also need to be compatible with post-vaccination screening methods to determine whether or not animals continue to be infected. Requirements and prospects for new or improved vaccines are described for some priority viral diseases with potential for transboundary spread, particularly for foot-and-mouth disease.

[1]  Zhidong Zhang,et al.  Foot-and-Mouth Disease Virus Persists in the Light Zone of Germinal Centres , 2008, PloS one.

[2]  B. Chomel,et al.  Risques d’introduction et d’implantation en Europe de maladies infectieuses exotiques , 2009 .

[3]  J. Lubroth,et al.  Experience with eradicating rinderpest by vaccination. , 2004, Developments in biologicals.

[4]  S. Reid,et al.  Interferon-gamma production in vitro from whole blood of foot-and-mouth disease virus (FMDV) vaccinated and infected cattle after incubation with inactivated FMDV. , 2006, Vaccine.

[5]  K. Karaca,et al.  Recombinant canarypox virus vaccine co-expressing genes encoding the VP2 and VP5 outer capsid proteins of bluetongue virus induces high level protection in sheep. , 2007, Vaccine.

[6]  J. Wilesmith,et al.  Modelling studies to estimate the prevalence of foot-and-mouth disease carriers after reactive vaccination , 2008, Proceedings of the Royal Society B: Biological Sciences.

[7]  R. Singh,et al.  The current status of sheep pox disease. , 2006, Comparative immunology, microbiology and infectious diseases.

[8]  S. Zanker,et al.  Animal vaccination and the veterinary pharmaceutical industry. , 2007, Revue scientifique et technique.

[9]  J. Suzich,et al.  Baculovirus expression of the M genome segment of Rift Valley fever virus and examination of antigenic and immunogenic properties of the expressed proteins. , 1989, Virology.

[10]  P. Roy,et al.  Bluetongue vaccines. , 2009, Vaccine.

[11]  S. Barros,et al.  A DIVA system based on the detection of antibodies to non-structural protein 3 (NS3) of bluetongue virus. , 2009, Veterinary microbiology.

[12]  C. Batten,et al.  Global distribution of peste des petits ruminants virus and prospects for improved diagnosis and control. , 2010, The Journal of general virology.

[13]  P. Roy,et al.  Development of Reverse Genetics Systems for Bluetongue Virus: Recovery of Infectious Virus from Synthetic RNA Transcripts , 2008, Journal of Virology.

[14]  P. Mellor,et al.  Viraemia and clinical disease in Dorset Poll sheep following vaccination with live attenuated bluetongue virus vaccines serotypes 16 and 4. , 2010, Vaccine.

[15]  M. Lombard,et al.  Antigen and vaccine banks: technical requirements and the role of the european antigen bank in emergency foot and mouth disease vaccination. , 2007, Revue scientifique et technique.

[16]  P. Mertens,et al.  A competitive ELISA for the detection of anti-tubule antibodies using a monoclonal antibody against bluetongue virus non-structural protein NS1. , 1993, Journal of virological methods.

[17]  Zhiyong Li,et al.  FMD subunit vaccine produced using a silkworm-baculovirus expression system: protective efficacy against two type Asia1 isolates in cattle. , 2011, Veterinary microbiology.

[18]  F. Maree,et al.  Custom-engineered chimeric foot-and-mouth disease vaccine elicits protective immune responses in pigs. , 2011, The Journal of general virology.

[19]  M. Bouloy,et al.  Rift Valley fever virus (Bunyaviridae: Phlebovirus): an update on pathogenesis, molecular epidemiology, vectors, diagnostics and prevention , 2010, Veterinary research.

[20]  M. Sinclair,et al.  Qualitative assessment of the commodity risk for spread of foot-and-mouth disease associated with international trade in deboned beef. , 2010, Transboundary and emerging diseases.

[21]  M. Jeggo,et al.  A study of the role of cell-mediated immunity in bluetongue virus infection in sheep, using cellular adoptive transfer techniques. , 1984, Immunology.

[22]  B. Coupar,et al.  Antibody responses and protective immunity to recombinant vaccinia virus-expressed bluetongue virus antigens. , 1997, Veterinary immunology and immunopathology.

[23]  E. Domingo,et al.  Foot-and-mouth disease virus. , 2002, Comparative immunology, microbiology and infectious diseases.

[24]  J. Sánchez-Vizcaíno,et al.  Vaccines against bluetongue in Europe. , 2008, Comparative immunology, microbiology and infectious diseases.

[25]  S. Gubbins,et al.  Foot-and-Mouth Disease Virus Can Induce a Specific and Rapid CD4+ T-Cell-Independent Neutralizing and Isotype Class-Switched Antibody Response in Naïve Cattle , 2009, Journal of Virology.

[26]  M. Jeggo,et al.  Importance of ovine cytotoxic T cells in protection against bluetongue virus infection. , 1985, Progress in clinical and biological research.

[27]  G. Nabel,et al.  Induction of Broadly Neutralizing H1N1 Influenza Antibodies by Vaccination , 2010, Science.

[28]  E. Domingo,et al.  A large-scale evaluation of peptide vaccines against foot-and-mouth disease: lack of solid protection in cattle and isolation of escape mutants , 1997, Journal of virology.

[29]  D. Paton,et al.  Strategies for differentiating infection in vaccinated animals (DIVA) for foot-and-mouth disease, classical swine fever and avian influenza , 2010, Expert review of vaccines.

[30]  H. R. Cox BLUETONGUE , 1954, CABI Compendium.

[31]  J. Valarcher,et al.  Selection of foot and mouth disease vaccine strains--a review. , 2005, Revue scientifique et technique.

[32]  J. Y. Scheerlinck,et al.  Genetic adjuvants for DNA vaccines. , 2001, Vaccine.

[33]  H. Takamatsu,et al.  In vivo depletion of CD8+ T lymphocytes abrogates protective immunity to African swine fever virus. , 2005, The Journal of general virology.

[34]  H. Thulke,et al.  High potency vaccines induce protection against heterologous challenge with foot-and-mouth disease virus. , 2008, Vaccine.

[35]  L. Dixon,et al.  African swine fever: how can global spread be prevented? , 2009, Philosophical Transactions of the Royal Society B: Biological Sciences.

[36]  P. Roy,et al.  Rift Valley fever virus structural proteins: expression, characterization and assembly of recombinant proteins , 2008, Virology Journal.

[37]  B. Charleston,et al.  Global FMD control--is it an option? , 2007, Vaccine.

[38]  P. Mellor,et al.  Expression of the major core structural protein (VP7) of bluetongue virus, by a recombinant capripox virus, provides partial protection of sheep against a virulent heterotypic bluetongue virus challenge. , 1996, Virology.

[39]  M. Greiner,et al.  Application of non-structural protein antibody tests in substantiating freedom from foot-and-mouth disease virus infection after emergency vaccination of cattle. , 2006, Vaccine.

[40]  M. Grubman Development of novel strategies to control foot-and-mouth disease: marker vaccines and antivirals. , 2005, Biologicals : journal of the International Association of Biological Standardization.

[41]  T. Barrett,et al.  Matrix protein and glycoproteins F and H of Peste-des-petits-ruminants virus function better as a homologous complex. , 2006, The Journal of general virology.

[42]  R. May,et al.  Modelling vaccination strategies against foot-and-mouth disease , 2003, Nature.

[43]  Kehe Huang,et al.  A goat poxvirus-vectored peste-des-petits-ruminants vaccine induces long-lasting neutralization antibody to high levels in goats and sheep. , 2010, Vaccine.

[44]  B. Charleston,et al.  Options for control of foot-and-mouth disease: knowledge, capability and policy , 2009, Philosophical Transactions of the Royal Society B: Biological Sciences.

[45]  R. Parkhouse,et al.  The non-haemadsorbing African swine fever virus isolate ASFV/NH/P68 provides a model for defining the protective anti-virus immune response. , 2001, The Journal of general virology.

[46]  M. Heise,et al.  An alphavirus replicon-derived candidate vaccine against Rift Valley fever virus , 2009, Epidemiology and Infection.

[47]  P. Roy,et al.  Validation of a novel approach for the rapid production of immunogenic virus-like particles for bluetongue virus. , 2010, Vaccine.

[48]  T. Barrett,et al.  Cell-mediated immune responses in cattle vaccinated with a vaccinia virus recombinant expressing the nucleocapsid protein of rinderpest virus. , 1999, The Journal of general virology.

[49]  G. Gerbier,et al.  Review of the status of foot and mouth disease and approach to control/eradication in Europe and Central Asia. , 2002, Revue scientifique et technique.

[50]  T. Barrett,et al.  Rescue of a chimeric rinderpest virus with the nucleocapsid protein derived from peste-des-petits-ruminants virus: use as a marker vaccine , 2007, The Journal of general virology.

[51]  Camille Szmaragd,et al.  The Spread of Bluetongue Virus Serotype 8 in Great Britain and Its Control by Vaccination , 2010, PloS one.

[52]  G. Thomson,et al.  Certification for regional and international trade in livestock commodities: the need to balance credibility and enterprise , 2006, Veterinary Record.

[53]  T. Barrett,et al.  The threat of peste des petits ruminants: progress in vaccine development for disease control. , 2007, Vaccine.

[54]  F. Roger,et al.  Avian influenza vaccines: a practical review in relation to their application in the field with a focus on the Asian experience , 2008, Epidemiology and Infection.

[55]  V. Saraiva,et al.  Review of the status of foot and mouth disease in countries of South America and approaches to control and eradication. , 2002, Revue scientifique et technique.

[56]  K. McCullough,et al.  Protective immune response against foot-and-mouth disease , 1992, Journal of virology.

[57]  M. Habjan,et al.  Vaccination with virus-like particles protects mice from lethal infection of Rift Valley Fever Virus. , 2009, Virology.

[58]  G. Viljoen,et al.  Protective immune responses induced by different recombinant vaccine regimes to Rift Valley fever. , 2006, Vaccine.

[59]  T. Ksiazek,et al.  Rift Valley fever virus. , 2009, Journal of the American Veterinary Medical Association.

[60]  G. Nabel,et al.  Enhanced Breadth of CD4 T-Cell Immunity by DNA Prime and Adenovirus Boost Immunization to Human Immunodeficiency Virus Env and Gag Immunogens , 2005, Journal of Virology.

[61]  H. Siegismund,et al.  Low diversity of foot-and-mouth disease serotype C virus in Kenya: evidence for probable vaccine strain re-introductions in the field , 2010, Epidemiology and Infection.

[62]  Zhiyong Li,et al.  The current state of vaccines used in the field for foot and mouth disease virus in China , 2011, Expert review of vaccines.

[63]  T. Ksiazek,et al.  Rift Valley Fever Virus Lacking the NSs and NSm Genes Is Highly Attenuated, Confers Protective Immunity from Virulent Virus Challenge, and Allows for Differential Identification of Infected and Vaccinated Animals , 2008, Journal of Virology.

[64]  Yanmin Li,et al.  Dramatic improvement in FMD DNA vaccine efficacy and cross-serotype antibody induction in pigs following a protein boost. , 2008, Vaccine.